ImpriMed

ImpriMed uniquely combines live-cell drug sensitivity testing, flow cytometry, and PARR clonality analysis to power machine-learning models that predict individualized chemotherapy response profiles for dogs with lymphoma and leukemia, including CHOP protocol outcomes. Unlike conventional diagnostics, it delivers AI-generated likelihood scores for both single-agent and combination drug efficacy, supported by real-world progression-free survival metrics and expert consult access—enabling personalized treatment planning grounded in functional tumor biology.